Results 51 to 60 of about 39,021 (326)

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma

Frontiers in Oncology, 2022
Majority of patients with resected early- and intermediate-stage liver cancer will experience postoperative recurrence. This study aimed to investigate the application of ctDNA sequencing in the postoperative period of hepatocellular carcinoma.
Ke Ye, Qinqiao Fan, Mingming Yuan, Dong Wang, Liang Xiao, Guo Long, Rongrong Chen, Tongdi Fang, Zengbo Li, Ledu Zhou   +9 more
doaj   +1 more source

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. [PDF]

, 2018
BackgroundNew prognostic markers are needed to identify patients with Ewing sarcoma (EWS) and osteosarcoma unlikely to benefit from standard therapy.
Barkauskas, Donald A, Clapp, Andrea, Crompton, Brian D, DuBois, Steven G, Gorlick, Richard, Ha, Gavin, Hall, David, Imamovic-Tuco, Alma, Janeway, Katherine A, Klega, Kelly, Krailo, Mark D, Leavey, Patrick J, Lessnick, Stephen L, London, Wendy B, Mascarenhas, Leo, Nag, Anwesha, Shulman, David S, Stegmaier, Kimberly, Thorner, Aaron R, Van Allen, Eliezer, Vo, Kieuhoa T   +20 more
core   +1 more source

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative [PDF]

, 2016
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies.
Aberra, Metasebia, Bender, R. Joseph, Brody, Jonathan, Chung, Vincent, Heartwell, Craig, Hendifar, Andrew, Hoos, William A., Madhavan, Subha, Mason, Kimberly, Matrisian, Lynn M., Mikhail, Sam, Petricoin, Emanuel, III, Picozzi, Vincent, Pishvaian, Michael J., Rahib, Lola, Varieur, Katelyn   +15 more
core   +2 more sources

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

The rationale for liquid biopsy in colorectal cancer: focus on circulating tumor cells [PDF]

, 2015
Capturing circulating tumor cells (CTCs) and/or circulating tumor DNA from blood, which represents a precious source of biological material derived from both primary and metastatic tumors, has been named a 'liquid biopsy'. While the circulating tumor DNA
Carletti, Raffaella, Cortesi, Enrico, DI GIOIA, Cira Rosaria Tiziana, Gazzaniga, Paola, Gradilone, Angela, Nicolazzo, Chiara, Raimondi, Cristina   +6 more
core   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Application of liquid biopsy in lung cancer management

Indian Journal of Pathology and Microbiology
Current advances in the understanding of the lung cancer landscape have drastically changed the approach to treating a patient with lung carcinoma. The field has progressed from analyzing single gene to using advanced techniques like next-generation ...
Shraddhanjali Satapathy, Balamurugan Thirunavukkarasu, Deepali Jain   +2 more
doaj   +1 more source

Release of DNA and surfactant from gel particles: The receptor solution effect and the dehydration-hydration aspects [PDF]

, 2014
DNA and cetyltrimethylammonium bromide (CTAB) have been used to prepare gel particles for controlled release studies. This article reports on the release of DNA and CTAB in four different solutions: in sodium bromide, in strong acid, pH 2 and pH 9 ...
Mezei, Amália, Pons Pons, Ramon
core   +1 more source